On April 16, 2024, Asher Biotherapeutics, Inc. closed the transaction. The company received $55,000,000 in a round of funding led by returning investor, RA Capital Management, L.P. The transaction included participation from new investors, AstraZeneca PLC, Bristol-Myers Squibb Company, returning investors Janus Henderson Investors US LLC, Third Rock Ventures, LLC, Wellington Management Company LLP, Boxer Capital LLC and other undisclosed institutional investors. The transaction included participation from 16 investors pursuant to regulation D.